CORC

在结果中检索

CORC

浏览/检索结果: 共41条，第1-10条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：46/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：36/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：39/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：30/0  |  提交时间：2019/12/05
An Improved Total Variation Denoising Model 会议论文
12th International Conference on e-Learning and Games, Edutainment 2018, Xi'an, China, 2018-06-28
作者:  Zhao, Minghua;  Chen, Tang;  Shi, Zhenghao;  Li, Peng;  Li, Bing
收藏  |  浏览/下载：6/0  |  提交时间：2019/12/20
Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 会议论文
作者:  Wei, Lai;  Xu, Xiaoyun;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Jifang
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05
Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 会议论文
作者:  Wei, Lai;  Xu, Xiaoyun;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Jifang
收藏  |  浏览/下载：11/0  |  提交时间：2019/11/19
Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 会议论文
作者:  Wei, Lai;  Xu, Xiaoyun;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Jifang
收藏  |  浏览/下载：10/0  |  提交时间：2019/12/05
Potential Metabolite Markers of Multiple Myeloma 会议论文
BLOOD, 2018-11-29
作者:  Xia, Jiliang;  Zhang, Jingyu;  Wu, Xuan;  Chen, ShiLian;  Lin, Jingchao
收藏  |  浏览/下载：31/0  |  提交时间：2020/01/03

©版权所有 ©2017 CSpace - Powered by CSpace